TABLE 2.
Summary of the number of cats with transient viremia, persistent viremia, and latent infection following challenge
| Group | DNA inoculum | Gene adjuvant | No. of animals with:
|
No. of animals with persistent and latent infections/total no. | ||
|---|---|---|---|---|---|---|
| Transient viremiaa/total no. | Persistent viremia/total no. | Additional latent infection/total no. | ||||
| A | FeLV env + gag/pol | None | 1/6 | 2/6 | 2/6 | 4/6 |
| B | FeLV env + gag/pol | IFN-γ | 0/5 | 2/5 | 0/5 | 2/5 |
| C | FeLV env + gag/pol | IL-12 | 0/6 | 4/6 | 0/6 | 4/6 |
| D | FeLV env + gag/pol | IL-12 + IL-18 | 0/6 | 0/6 | 1/6 | 1/6 |
| E | pCI-neo plasmid | None | 2/6 | 3/6 | 2/6 | 5/6 |
a
Transient viremia defined as viremia at 3 weeks postchallenge that is cleared by 6 weeks postchallenge.